The short version of human growth hormone fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-04-16. Anything still debated is marked as such rather than presented as settled.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
| Property | Value | Notes |
|---|---|---|
| Common name | AOD-9604 | Development code used in scientific literature. |
| Chemical class | Synthetic peptide | Fragment of human growth hormone. |
| Amino acid length | 16 residues | Matches hGH region 176-191. |
| Appearance | White to off-white powder | Typical lyophilized peptide solid. |
| Solubility | Soluble in water | Dissolves in aqueous media; exact behavior depends on salt form. |
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
In bacterial cells, ribosomes are synthesized in the cytoplasm through the transcription of multiple ribosome gene operons. In eukaryotes, the process takes place both in the cell cytoplasm and in the nucleolus, which is a region within the cell nucleus. The assembly process involves the coordinated function of over 200 proteins in the synthesis and processing of the four rRNAs, as well as assembly of those rRNAs with the ribosomal proteins.
== Epidemiology == The condition affects adults more frequently than children and males more frequently than females. Most cases occur between the ages of 40 and 60. Polyarteritis nodosa is more common in people with hepatitis B infection.
== External links == Waite, Mike. "Democratic Left day conference: Radical Roots, London, 14 December 1996". Communist History Network Newsletter. Politics Section of the School of Social Sciences at the University of Manchester. Archived from the original on 17 July 2011. Retrieved 9 February 2010. Democratic Left on the Internet Archive
=== Chubby Chicken === Another 1960s-era offering, Chubby Chicken, returned to the menu shortly after the reintroduction of the Burger Family. Chubby burgers are breaded all white-meat chicken breasts. There are three varieties offered:
The main preparation of the drug commercially available is mixed with cyclizine (Diconal, Wellconal) which has the advantage of reducing nausea, vomiting and histamine release associated with strong opioid therapy. Dipipanone was also available as an oral mixture 10 mg/5 mL without the cyclizine during the 1970s–1980s in the United Kingdom. This form was rare and used normally only in drug trials and in specialist Diconal addiction clinics. Dipipanone is now the only alternative opioid left to use in the UK that is of equal strength to morphine that can be prescribed instead, aside from oxycodone and hydromorphone which are typically the second and third-line alternative to pain relief when morphine is indicated but not tolerated. A fentanyl patch may also be used, especially in cases of renal impairment. One of the limitations of using dipipanone is that it is only produced in one dosage form that is mixed with the anti-emetic and anti-histamine cyclizine at a ratio of 25% dipipanone to 75% cyclizine which limits the dose of dipipanone to an absolute maximum of 3 tablets per dose up to 4–6 times a day. This is a 10 mg dipipanone and 30 mg cyclizine formulation. It is made by the following manufacturers:
Sources: en.wikipedia.org
detailed family history conducting a detailed physical examination to document morphological features testing for genetic defect in FGDY1 x-rays can identify skeletal abnormalities echo cardiogram can screen for heart abnormalities CT scan of the brain for cystic development X-ray of the teeth Ultrasound of abdomen to identify undescended testis Similar to all genetic diseases Aarskog–Scott syndrome cannot be cured, although numerous treatments exist to increase the quality of life. Surgery may be required to correct some of the anomalies, and orthodontic treatment may be used to correct some of the facial abnormalities. Trials of growth hormone have been effective to treat short stature in this disorder. Some people may have some mental slowness, but children with this condition often have good social skills. Some males may have problems with fertility. The syndrome is named for Dagfinn Aarskog, a Norwegian pediatrician and human geneticist who first described it in 1970, and for Charles I. Scott, Jr., an American medical geneticist who independently described the syndrome in 1971.
Anthony Tiran Todd (December 4, 1954 – November 6, 2024) was an American actor. Known for his distinctly deep and gravelly voice, he amassed numerous credits on screen and in video games since the 1980s, including the title character in the Candyman film series (1992–2021) and William Bludworth in the Final Destination franchise (2000–2025). For the former, he was nominated at the Critics' Choice and Fangoria Chainsaw Awards. Todd's films include Platoon (1986), Night of the Living Dead (1990), The Crow (1994), The Rock (1996), Wishmaster (1997), Hatchet, Minotaur (both 2006), The Man from Earth (2007), Frankenstein (2015), Death House (2017), and Hell Fest (2018). On television, he played Kurn in Star Trek: The Next Generation (1990–1991) and Star Trek: Deep Space Nine (1996), Lord Haikon on Stargate SG-1 (2005–2006), and appeared in the MTV series Scream (2019) and Devil May Cry (2025). Todd was a prolific voice actor, notably voicing the Vortigaunts in the Half-Life series of games, the Fallen in Michael Bay's Transformers: Revenge of the Fallen (2009), Zoom in The Flash (2014–2023), Darkseid in the DC Animated Movie Universe (2015–2020), Venom in the video game Marvel's Spider-Man 2 (2023), and Locus in the video game Indiana Jones and the Great Circle (2024). For Spider-Man 2, he received a British Academy Games Award nomination.
Iodine in food is absorbed by the body and preferentially concentrated in the thyroid where it is needed for the functioning of that gland. When 131I is present in high levels in the environment from radioactive fallout, it can be absorbed through contaminated food, and will also accumulate in the thyroid. As it decays, it may cause damage to the thyroid. The primary risk from exposure to 131I is an increased risk of radiation-induced cancer in later life. Other risks include the possibility of non-cancerous growths and thyroiditis. The risk of thyroid cancer in later life appears to diminish with increasing age at time of exposure. Most risk estimates are based on studies in which radiation exposures occurred in children or teenagers. When adults are exposed, it has been difficult for epidemiologists to detect a statistically significant difference in the rates of thyroid disease above that of a similar but otherwise-unexposed group. The risk can be mitigated by taking iodine supplements, raising the total amount of iodine in the body and, therefore, reducing uptake and retention in the face and chest and lowering the relative proportion of radioactive iodine. However, such supplements were not consistently distributed to the population living nearest to the Chernobyl nuclear power plant after the disaster, though they were widely distributed to children in Poland. Within the US, the highest 131I fallout doses occurred during the 1950s and early 1960s to children having consumed fresh milk from sources contaminated as the result of above-ground testing of nuclear weapons.
In the Bronze Age, the Hellenes had trade and cultural contacts with Egypt. Before the time that Alexander the Great occupied Egypt, the Greek name, sphinx, was already applied to these statues. The historians and geographers of Greece such as Herodotus wrote extensively about Egyptian culture. There was a single sphinx in Greek mythology, a unique demon of destruction and bad luck. Apollodorus describes the sphinx as having a woman's face, the body and tail of a lion and the wings of a bird. Pliny the Elder mentions that Ethiopia produces plenty of sphinxes, with brown hair and breasts, corroborated by 20th-century archeologists. Statius describes her as a winged monster, with pallid cheeks, eyes tainted with corruption, plumes clotted with gore and talons on livid hands. John Tzetzes described her as having the front of a lion, the rear of a human, the wings of a griffin and the claws of an eagle. Sometimes, the wings are specified to be those of an eagle, and the tail to be serpent-headed. According to Hesiod, the Sphinx was a daughter of Orthrus and an unknown she—either the Chimera, Echidna, or Ceto. According to Apollodorus and Lasus, she was a daughter of Echidna and Typhon. The sphinx was the emblem of the ancient city-state of Chios, and appeared on seals and the obverse side of coins from the 6th century BC until the 3rd century AD.
Pre-adipocytes are undifferentiated fibroblasts that can be stimulated to form adipocytes. Studies have shed light into potential molecular mechanisms in the fate determination of pre-adipocytes although the exact lineage of adipocyte is still unclear. The variation of body fat distribution resulting from normal growth is influenced by nutritional and hormonal status dependent on intrinsic differences in cells found in each adipose depot. Mesenchymal stem cells can differentiate into adipocytes, connective tissue, muscle or bone. The precursor of the adult cell is termed a lipoblast, and a tumor of this cell type is known as a lipoblastoma.
Sources: en.wikipedia.org
== Veterinary use == Combined with marbofloxacin CAS number 115550-35-1and clotrimazole, dexamethasone is available under the name Aurizon, CAS number 50-02-2, and used to treat difficult ear infections, especially in dogs. It can also be combined with trichlormethiazide to treat horses with swelling of distal limbs and general bruising. Dexamethasone is also used for emergency patients with hypoadrenocorticism as the drug does not interfere with adrenocorticotropic hormone stimulation testing.
Connor (1961), White House cabinet secretary and staff secretary to President Gerald Ford Brooks Firestone (1961), member of the California State Assembly from the 35th district 1994–1998, founder of Firestone Vineyard and grandson of Harvey S. Firestone Harvey Goldschmid (1962), professor at Columbia Law School, commissioner of the U.S. Securities and Exchange Commission 2002–2005 John A. McMullen (1963), Vermont businessman and Republican Party candidate for the United States Senate representing Vermont in 1998, 2004, and Vermont Attorney General in 2012 Jeff Bell (1965), Republican nominee for United States Senate from New Jersey in 1978, 1982, and in 2014 Mark T. Cox IV (1966), former United States alternate executive director to the World Bank Allan I. Mendelowitz (1966), former chairman and director of the Federal Housing Finance Board Raymond Burghardt (1967), former director, and chairman of the American Institute in Taiwan and U.S. Ambassador to Vietnam Dick Morris (1967), political strategist and advisor to President Bill Clinton and Mexican President Felipe Calderón Mark C. Minton (1967), former U.S. ambassador to Mongolia, and former president of the Korea Society Robert Delahunty (1968), deputy general counsel, White House Office of Homeland Security 2002–2003; professor at University of St. Thomas School of Law Judd Gregg (1969), United States senator from New Hampshire; governor of New Hampshire; U.S. congressman Jerrold Nadler (1969), U.S. congressman from New York Daniel L.
US pathology firm CPL-Clinical Pathology Laboratories for $US123.5 million (A$121.5 million). In 2010, Sonic Healthcare acquired Labor Lademannbogen (Hamburg, Germany) and Medhold Group (Antwerp, Belgium), and through the IPN the Prime Health Group. In the US, the company acquired CBLPath (Rye Brook, NY) and Physician's Automated Laboratory (Bakersfield, California).
=== Basic Life Support === Opioid overdose leads to death when people stop breathing. Bystanders trained in first aid can evaluate people who have overdosed and provide basic life support including rescue breathing via bag valve mask or mouth to mouth. If the person who has overdosed does not have a pulse, rescuers should begin CPR.
Natural CEEs, as Premarin, are available in the form of oral tablets (0.3 mg, 0.625 mg, 0.9 mg, 1.25 mg, or 2.5 mg), creams for topical or vaginal administration (0.625 mg/g), and vials for intravenous or intramuscular injection (25 mg/vial). Synthetic CEEs, such as Cenestin (Synthetic A), Enjuvia (Synthetic B), and generic formulations, are available in the form of oral tablets (0.3 mg, 0.45 mg, 0.625 mg, 0.9 mg, or 1.25 mg) and creams for topical or vaginal administration (0.625 mg/g).
Sources: en.wikipedia.org
AOD-9604 is a synthetic peptide fragment of human growth hormone. It corresponds to the C-terminal region known as hGH 176-191 and is studied for metabolic effects. It is not an approved therapeutic drug.
No. It contains only a small portion of the human growth hormone sequence. The full hormone has 191 amino acids and many additional actions that the fragment does not share.
The name refers to the amino acid positions in the human growth hormone chain. The fragment spans residues 176 through 191 at the C-terminal end. This naming convention helps distinguish it from full-length hGH.
It is a synthetic peptide fragment derived from the C-terminal region of human growth hormone, commonly referred to as hGH fragment 176-191. It has been investigated for effects on fat metabolism, but it is not an approved medication in most jurisdictions.